CIRM Funded Clinical Trials

The CuRe Trial: Cellular Therapy for In Utero Myelomeningocele Repair


Diana Farmer
Disease Area: 
Spina Bifida
Investigator:
CIRM Grant:
CLIN2-12129 (Pre-Active)
Award Value:
$8,996,474
Trial Stage: 
Phase 1
Trial Status: 
Launching
Targeted Enrollment:
N/A
Details: 

UC Davis is conducting a clinical trial for in utero repair of myelomeningocele (MMC), the most severe form of spina bifida.  MMC is a birth defect that occurs due to incomplete closure of the developing spinal cord, resulting in neurological damage to the exposed cord.  This damage leads to lifelong lower body paralysis, and bladder and bowel dysfunction.

The team will use placenta tissue to generate mesenchymal stem cells (MSCs).  The newly generated MSCs will be seeded onto an FDA approved dural graft and the product will be applied to the spinal cord while the infant is still developing in the womb.  The goal of this therapy is to help promote proper spinal cord formation and improve motor function, bladder function, and bowel function. 

Design: 

This is a Phase I/IIA clinical trial. 

Goal: 

To evaluate safety and preliminary efficacy.